As the Academic Lead in Biomedical Science and an Associate Professor (Professional Practice) I have an international reputation in the Alzheimer's Drug Discovery and Diagnostics research field. I am a Fellow of the Royal Society of Biology (FRSB) and Institute of Biomedical Sciences (FIBMS).

I have led a research group, which conducts research into identification of target protein binding molecules. The focus of my research has been biochemical interactions of amyloid peptides and their role in Alzheimer's disease, Diabetes, Creutzfeldt-Jakob disease and oxidative stress responses. I discovered the neuroprotective actions of cannabinoids in an Alzheimer's disease cell culture model. I also discovered the kissorphin derivative of the kisspeptin peptide as an anti-opioid peptide. Both kisspeptin and kissorphin peptides are neuroprotective in an Alzheimer's disease cell culture model.

I have also used bioinformatics, aptamer, molecular biology, biochemical and cell biology techniques to discover and characterize the mechanisms of neuroprotection of a number of compounds. I have teaching experience, at both undergraduate and postgraduate levels, in the areas of Physiology, Pharmacology, Clinical Biochemistry, Neuroscience and Bioentrepreneurship.

I am an entrepreneur and have filed a number of patent applications, one of which, for use of kissorphin peptides, was granted in the UK and others which were taken to the intention to grant stage in Europe. I founded an in silico based company, Neurodelta Ltd and raised government funding for commercial research in the Alzheimer’s Drug Discovery and Diagnostic area.